Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Daewoong starts phase I trial for its three-drug combo
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Feb 21, 2014 17:06:12
Daewoong will start its phase I clinical trial for DWJ1351, a new combination drug of amlodipine, olmesartan, and rosuvastatin.

According to the Ministry of Food and Drug Safety, Daewoong got approval for its protocol for a phase I clinical trial for DWJ1351. Samsung Seoul Hospital will conduct the trial to find interactions among three agents.

DWJ1351 can be considered as a combo of Sevikar and Crestor. Sevikar sales were 50 billion won and Crestor sales were 90 billion won last year.

Sevikar HCT, a combo of Sevikar and hydrochlorothiazide, is already available on the market.

Other Korean drugmakers are also conducting their clinical trials for three-drug combos to treat both hypertension and hypercholesterolemia.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com